Assess whether pediatric studies are necessary or waivable (fcd4bc)

Situation

The CMC and Development Pathways desk packet is biosimilar analytical similarity report after a boxed-warning proposal from the review division. CMC change-control owner in a rare-disease team designing a pediatric plan must name Pediatric studies are necessary or Waivable for this Pharma & Life Sciences file. CMC change-control owner in a rare-disease team designing a pediatric plan has to name Pediatric studies are necessary or Waivable for this Pharma & Life Sciences CMC and Development Pathways file.

Decision

CMC change-control owner in a rare-disease team designing a pediatric plan must choose Pediatric studies are necessary / Waivable using biosimilar analytical similarity report after a boxed-warning proposal from the review division.

Hypotheses to test

• Authorize Pediatric studies are necessary now; biosimilar analytical similarity report already has the discriminator after a boxed-warning proposal from the review division.
• Keep Waivable in force until biosimilar analytical similarity report is completed after a boxed-warning proposal from the review division for CMC change-control owner.
• Treat biosimilar analytical similarity report as Pediatric studies are necessary because both readings appear after a boxed-warning proposal from the review division.
• Refuse a Pharma & Life Sciences close: CMC change-control owner does not have the page pediatric studies are necessary turns on in biosimilar analytical similarity report.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• Check whether biosimilar analytical similarity report supports the labeled claim CMC change-control owner would keep.
• For this Pharma & Life Sciences CMC and Development Pathways file, read biosimilar analytical similarity report against a boxed-warning proposal from the review division and write the one fact that would move pediatric studies are necessary for CMC change-control owner.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / CMC and Development Pathways packet (biosimilar analytical similarity report after a boxed-warning proposal from the review division). The follow-on CMC and Development Pathways action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.